Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;40(6):e3842.
doi: 10.1002/dmrr.3842.

Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis

Sergio Di Molfetta  1 , Ludovico Di Gioia  1 , Irene Caruso  1 , Angelo Cignarelli  1 , Suetonia C Green  2 , Patrizia Natale  3   4   5 , Giovanni F M Strippoli  3   4 , Gian Pio Sorice  1 , Sebastio Perrini  1 , Annalisa Natalicchio  1 , Luigi Laviola  1 , Francesco Giorgino  1
Affiliations

Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis

Sergio Di Molfetta et al. Diabetes Metab Res Rev. 2024 Sep.

Abstract

Aims: To compare the efficacy and safety of different hybrid closed loop (HCL) systems in people with diabetes through a network meta-analysis.

Methods: We searched MEDLINE, EMBASE, CENTRAL and PubMed for randomised clinical trials (RCTs) enrolling children, adolescents and/or adults with type 1 or type 2 diabetes, evaluating Minimed 670G, Minimed 780G, Control-IQ, CamAPS Fx, DBLG-1, DBLHU, and Omnipod 5 HCL systems against other types of insulin therapy, and reporting time in target range (TIR) as outcome.

Results: A total of 28 RCTs, all enrolling people with type 1 diabetes, were included. HCL systems significantly increased TIR compared with subcutaneous insulin therapy without continuous glucose monitoring (SIT). Minimed 780G achieved the highest TIR ahead of Control IQ (mean difference (MD) 5.1%, 95% confidence interval (95% CI) [0.68; 9.52], low certainty), Minimed 670G (MD 7.48%, 95% CI [4.27; 10.7], moderate certainty), CamAPS Fx (MD 8.94%, 95% CI [4.35; 13.54], low certainty), and DBLG1 (MD 10.69%, 95% CI [5.73; 15.65], low certainty). All HCL systems decreased time below target range, with DBLG1 (MD -3.69%, 95% CI [-5.2; -2.19], high certainty), Minimed 670G (MD -2.9%, 95% CI [-3.77; -2.04], moderate certainty) and Minimed 780G (MD -2.79%, 95% CI [-3.94; -1.64], high certainty) exhibiting the largest reductions compared to SIT. The risk of severe hypoglycaemia and diabetic ketoacidosis was similar to other types of insulin therapy.

Conclusions: We show a hierarchy of efficacy among the different HCL systems in people with type 1 diabetes, thus providing support to clinical decision-making.

Trial registration: PROSPERO CRD42023453717.

Keywords: Time In Range; automated insulin delivery; hybrid closed loop; type 1 diabetes.

PubMed Disclaimer

References

    1. J. C. Pickup and A. J. Sutton, “Severe Hypoglycaemia and Glycaemic Control in Type 1 Diabetes: Meta‐Analysis of Multiple Daily Insulin Injections Compared With Continuous Subcutaneous Insulin Infusion,” Diabetic Medicine 25, no. 7 (2008): 765–774, https://doi.org/10.1111/j.1464‐5491.2008.02486.x.
    1. I. Dicembrini, C. Cosentino, M. Monami, E. Mannucci, and L. Pala, “Effects of Real‐Time Continuous Glucose Monitoring in Type 1 Diabetes: A Meta‐Analysis of Randomized Controlled Trials,” Acta Diabetologica 58, no. 4 (2021): 401–410, https://doi.org/10.1007/s00592‐020‐01589‐3.
    1. M. Castellana, C. Parisi, S. Di Molfetta, et al., “Efficacy and Safety of Flash Glucose Monitoring in Patients With Type 1 and Type 2 Diabetes: A Systematic Review and Meta‐Analysis,” BMJ Open Diabetes Research & Care 8 (2020): e001092, https://doi.org/10.1136/bmjdrc‐2019‐001092.
    1. S. Di Molfetta, I. Caruso, A. Cignarelli, et al., “Professional Continuous Glucose Monitoring in Patients With Diabetes Mellitus: A Systematic Review and Meta‐Analysis,” Diabetes, Obesity and Metabolism 25, no. 5 (2023): 1301–1310, https://doi.org/10.1111/dom.14981.
    1. S. Charleer, C. Mathieu, F. Nobels, et al., “Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real‐World Study,” Journal of Clinical Endocrinology & Metabolism 103, no. 3 (2018): 1224–1232, https://doi.org/10.1210/jc.2017‐02498.

Publication types

MeSH terms